- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04688996
Yersinia Pestis Lateral Flow Immunoassay for Blood Samples (SMARTPRT)
Point of Care Diagnostic to Identify the Causative Agent of the Plague in Blood Samples
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study will be to generate the data required to thoroughly validate the ability of plague LFI assay (Lateral Flow Immunoassay) to accurately diagnose human infections with Y. pestis. These validation data will eventually be presented to US Food and Drug Administration (FDA; along with data from other studies that NAU will not participate) to seek approval for commercial license. The objective will be to validate this assay on the capillary blood of humans suspected to have plague as well as a study cohort likely to not have plague. From the suspected population; the specific aims of this study are to enroll up to 300 participants who present clinical signs of illness based on specific inclusion criteria. We will collect two types of blood samples from enrolled participants 1) capillary blood from a finger prick and 2) venous blood. The capillary blood will be used for direct testing on the LFI assay and the venous blood will be used to perform independent validations. This study is designed as a correlation study to understand 1) how LFI assay results compare with results from traditional diagnostic methods based on DNA detection methods and bacterial culture isolate on bubo aspirate or sputum and 2) effectiveness of capillary blood to serve as a diagnostic clinical sample as compared with traditional biological samples (venous blood, bubo and sputum). The study is designed to evaluate the outcome of LFI and how LFI results correlate with the standard plague diagnostics methods used in Madagascar and other methods. We are not examining the relationship between the results of the LFI and health outcomes of the participants. Decision of participant's medical treatment is solely based on the clinical judgment of the physician and guidelines set forth by Madagascar National Plague Control Program (PNLP); no formal test is involved with medical decision. All participants who are tested by LFI will have received medical treatment prior to the start of the study and the continuation of their medical treatment is guided by PNLP and physician judgment only. Again, we are not looking at the relationship between the results of the LFI and health outcomes of the participants.
From the non-suspect cohort, greater detail will be provided as obtained. In brief, this subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat). Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: David P Trudil
- Phone Number: 410-499-7062
- Email: Davidt@nhdetect.com
Study Contact Backup
- Name: Gregory R Siragusa, Ph.D.
- Phone Number: 262-309-5360
- Email: gsiragusa@nhdiag.com
Study Locations
-
-
Analamanga
-
Antananarivo, Analamanga, Madagascar, 101
- Recruiting
- Institut Pasteur de Madagascar
-
Contact:
- Voahangy Andrianaivoarimanana, Ph.D.
- Phone Number: 00261340654145
- Email: kekely@pasteur.mg
-
Contact:
- Minoarisoa RAJERISON, Ph.D>
- Phone Number: 00261341983916
- Email: mino@pasteur.mg
-
-
-
-
California
-
San Diego, California, United States, 92101
- Recruiting
- US Naval Health Research Center
-
Contact:
- Christopher A Myers, Ph.D.
- Phone Number: 619-756-8483
- Email: christopher.a.meyers48.civ@mail.mil
-
Contact:
- Caroline J Balagout
- Phone Number: 619-553-8950
- Email: caroline.j.balagot.ctr@mail.mil
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Malagasy Participants. Subjects will be recruited at rural health centers throughout Madagascar. Participants will be comprised of rural people with symptoms consistent with plague. The Madagascar Ministry of Public Health requires declaration of all suspected human plague cases and collection of biological samples (sputum and/or bubo aspirates) from these cases for medical workup for confirmation.
USN Health Center Participants. The subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat). Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.
Description
Inclusion criteria - Malagasy Participants
- Adults 18 to 75 years old (male and female): Able to receive and give verbal communication.
- Children 5 to 17 years old (vulnerable population): Parents or legal guardian must be available to give permission. Parents or legal guardian to consent for children (5-6 years).
- Suspected human plague case by local medical professional. Include at least one of the following: For bubonic plague: high fever, chills, and/or presence of painful bubo; For pneumonic plague: high fever, chills, cough for less than 5 days, bloody sputum, and/or chest pains; patients may be recruited from both plague surveillance program and non-plague surveillance programs.
Exclusion criteria - Malagasy Participants
- Children under the age of 5 years old
- Children between the age of 5 years to 17 years without a parent or legal guardian
- Not compliant with the study procedure (blood sampling)
Inclusion criteria - USN Health Center Participants
- Active duty personnel and DoD beneficiaries that present to participating study sites with influenza-like-illness (fever, cough, sore throat).
- Age range >=13 to 75 y.o.
- Able to receive/give consent (or assent if <18 y.o.) 4, Presenting with influenza-like-illness (fever of 100.5 F or higher, cough and/or sore throat)
5. USN Special Categories: Minors/children (45CFR Subpt. D/DoDI 3216.02, Encl 3, Para 7d); Students; Active duty military personnel (3216.02, Encl.3 Para. 7.e); Economically disadvantaged persons (32CFR 219.11(b); Educationally disadvantaged persons (32CFR 219.11(b).
Exclusion criteria - USN Health Center Participants
- <13 y.o.
- Unable to give written consent (if under 18)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Malagasy Participants
Malagasy Participants.
Subjects will be recruited at rural health centers throughout Madagascar.
Participants will be comprised of rural people with symptoms consistent with plague.
The Madagascar Ministry of Public Health requires declaration of all suspected human plague cases and collection of biological samples (sputum and/or bubo aspirates) from these cases for medical workup for confirmation.
|
A dipstick type of rapid test for antigens of the plague bacterium Yersinia pestis in samples from enrolled participants from both a known geography of plague activity (Madagascar) as well as samples from a geographically separated population of likely plague free status (US Naval Health Research Center, San Diego, CA).
Other Names:
|
USN Health Research Center
USN Health Center Participants.
The subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat).
Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.
|
A dipstick type of rapid test for antigens of the plague bacterium Yersinia pestis in samples from enrolled participants from both a known geography of plague activity (Madagascar) as well as samples from a geographically separated population of likely plague free status (US Naval Health Research Center, San Diego, CA).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LFI results on finger-prick blood correlate with the results of standard WHO-approved diagnostic tests for plague
Time Frame: Up to 3 weeks post sample collection and processing of each participant.
|
Description: Standard WHO-approved diagnostic testing uses bubo aspirates or sputum as clinical matrices to perform the following tests: F1RDT, qPCR analysis, and culture. WHO defines a confirmatory positive plague case when the bubo or sputum is positive on F1RDT and positive on either qPCR or culture. |
Up to 3 weeks post sample collection and processing of each participant.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LFI results on finger-prick blood correlate with LFI results from bubo aspirate or sputum clinical matrices.
Time Frame: Up to 3 weeks post sample collection and processing of each participant.
|
Standard WHO-approved diagnostic testing uses bubo aspirates or sputum as clinical matrices to perform the following tests: F1RDT, qPCR analysis, and culture. WHO defines a confirmatory positive plague case when the bubo or sputum is positive on F1RDT and positive on either qPCR or culture. |
Up to 3 weeks post sample collection and processing of each participant.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LFI results on finger-prick blood correlate with the test results on venous blood using the following diagnostic methods: LFI, qPCR, ELISA and FilmArray Warrior Panel.
Time Frame: Two years through sample collection and analysis completion from 05/2020 to 05/2022.
|
Standard WHO-approved diagnostic testing uses bubo aspirates or sputum as clinical matrices to perform the following tests: F1RDT, qPCR analysis, and culture. WHO defines a confirmatory positive plague case when the venous blood, bubo or sputum is positive on F1RDT and positive on either qPCR or culture. |
Two years through sample collection and analysis completion from 05/2020 to 05/2022.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dawn J Birdsell, Ph.D., Northern Arizona University
- Study Director: David M Wagner, Ph.D., Northern Arizona University
- Study Director: Minoarisoa Rajerison, Ph.D., Institut Pasteur de Madagascar
- Principal Investigator: Voahangy Andrianaivoarimanana, Ph.D., Institut Pasteur de Madagascar
- Study Director: Chris Myers, Ph.D., Naval Health Research Center
- Principal Investigator: Caroline Balagout, Naval Health Research Center
- Study Chair: David P Trudil, New Horizons Diagnostics, Inc./Brimrose Biotechnology, Corp.
Publications and helpful links
General Publications
- Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA. 2000 May 3;283(17):2281-90. doi: 10.1001/jama.283.17.2281.
- International meeting on preventing and controlling plague: the old calamity still has a future. Wkly Epidemiol Rec. 2006 Jul 14;81(28):278-84. No abstract available. English, French.
- Chanteau S, Rahalison L, Ralafiarisoa L, Foulon J, Ratsitorahina M, Ratsifasoamanana L, Carniel E, Nato F. Development and testing of a rapid diagnostic test for bubonic and pneumonic plague. Lancet. 2003 Jan 18;361(9353):211-6. doi: 10.1016/S0140-6736(03)12270-2.
- Stenseth NC, Atshabar BB, Begon M, Belmain SR, Bertherat E, Carniel E, Gage KL, Leirs H, Rahalison L. Plague: past, present, and future. PLoS Med. 2008 Jan 15;5(1):e3. doi: 10.1371/journal.pmed.0050003.
- Andrianaivoarimanana V, Kreppel K, Elissa N, Duplantier JM, Carniel E, Rajerison M, Jambou R. Understanding the persistence of plague foci in Madagascar. PLoS Negl Trop Dis. 2013 Nov 7;7(11):e2382. doi: 10.1371/journal.pntd.0002382. eCollection 2013 Nov.
- Rasoamanana B, Leroy F, Boisier P, Rasolomaharo M, Buchy P, Carniel E, Chanteau S. Field evaluation of an immunoglobulin G anti-F1 enzyme-linked immunosorbent assay for serodiagnosis of human plague in Madagascar. Clin Diagn Lab Immunol. 1997 Sep;4(5):587-91. doi: 10.1128/cdli.4.5.587-591.1997.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Lateral Flow Device
- Sputum
- Yersinia pestis Lateral Flow Device
- Point of Care testing, plague
- Point of Need testing, plague
- Plague
- Yersinia pestis
- Yersinia pestis antigens
- Yersinia pestis LcrV antigen
- Plague rapid test
- Yersinia rapid test
- Bubonic plague
- Bubo aspirate
- Pneumonic plague
- Yersinia pestis ELISA
- Yersinia pestis EIA
- Black plague
- Black death
- Yersinia LcrV protein
- Yersinia F1 antigen
- Yersinia PCR
- Lateral Flow Immunoassays
Additional Relevant MeSH Terms
Other Study ID Numbers
- Plague Lateral Flow Assay
- Evaluation of diagnostic tools (Other Identifier: Northern Arizona University)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plague
-
University of OxfordInstitut Pasteur de Madagascar; Hôpital Universitaire Joseph Raseta Befelatanana... and other collaboratorsRecruitingPlague, Bubonic | Plague, PneumonicMadagascar
-
Dynavax Technologies CorporationUnited States Department of DefenseActive, not recruitingVaccine-Preventable Diseases | Plague | Plague, PneumonicUnited States
-
DynPort Vaccine Company LLC, A GDIT CompanyCompleted
-
DynPort Vaccine Company LLC, A GDIT CompanyCompletedPneumonic Plague | Preventive TherapyUnited States
-
PharmAthene UK LimitedNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPlagueUnited States, United Kingdom
-
Jiangsu Province Centers for Disease Control and...Lanzhou Institute of Biological Products Co., LtdCompleted
-
Centers for Disease Control and PreventionMRC/UVRI and LSHTM Uganda Research Unit; Ministry of Health, UgandaUnknown
-
Centers for Disease Control and PreventionFood and Drug Administration (FDA); Ministry of Health, Uganda; Ministry of Health...Completed
-
Jiangsu Province Centers for Disease Control and...Active, not recruiting
-
National Institute of Allergy and Infectious Diseases...Completed
Clinical Trials on Lateral Flow Assay for Pathogens of the Plague
-
University of RochesterFogarty International Center of the National Institute of Health; Infectious... and other collaboratorsRecruiting
-
Karolinska InstitutetMbarara University of Science and Technology; Science for Life Laboratory; Epicentre... and other collaboratorsCompleted
-
CMC Ambroise ParéCompletedIsthmic Spondylolisthesis Treated With Combined Approach: Clinical and Radiological Outcomes (SPLAC)Surgical Procedure, Unspecified | Isthmic SpondylolisthesisFrance
-
Sequana Medical N.V.CompletedRefractory or Recurrent AscitesSpain, United Kingdom, Italy, France, Austria
-
University of PittsburghNational Institutes of Health (NIH)Recruiting
-
London Health Sciences CentreActive, not recruitingAntibody-mediated Rejection | Liver Transplant Failure
-
Riyadh Colleges of Dentistry and PharmacyKing Saud Medical CityUnknown
-
Centre Hospitalier Universitaire DijonUnknown
-
Memorial Sloan Kettering Cancer CenterRecruitingHPV-Related Malignancy | Oropharynx Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | HPVUnited States
-
Ege UniversityCompletedRegenerative EndodonticsTurkey